NCBI | Drug-resistant infections can strike anyone—young or old, healthy or sick. Dr. Helen Boucher examines the challenges, progress made in the discovery and development of new antibiotics, and the steps taken in the US to reduce disincentives in the reimbursement system of new antibiotics. While reimbursement reform and the proposed DISARM Act are encouraging first steps, salvaging the antibiotic research and development infrastructure will require more effort. Long-term solutions such as Market Entry Rewards are gaining traction but need further work in order to be realized. A leading expert in the field, Dr. Boucher calls on all physicians to be a voice for patients, and urge action. They should advocate for prompt publishing of data and updating of guidelines and for availability of new drugs in their hospitals. Most of all, physicians must reach out to legislators in support of DISARM (https://www.idsociety.org/ActOnDISARM) and get their colleagues involved. AMR affects everyone and threatens all medical care. An AMR movement is essential!